ABABVC BioPharma, Inc. ABVC · NASDAQ
$1.04 -0.95% (-$0.01)
- Market cap
- $24.3M
- Enterprise value
- $26.0M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -30.5x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -52.0%
- Gross margin
- 100.0%
- Net margin
- 992.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.51
- Free float
- 79.0%
About the company
ABVC BioPharma, Inc. is a biotechnology company focused on researching and developing new therapeutic approaches in the fields of oncology and immunotherapy. The company aims to discover drugs that can target specific immune mechanisms and potentially improve the treatment of various types of cancer. ABVC BioPharma strives to bring innovations to cancer treatment and support patients' immune systems in fighting the disease. Their research is directed towards developing drugs that can intervene in complex biological processes associated with cancer. Investors interested in the biotechnology sector and new therapeutic strategies in oncology might see potential in ABVC BioPharma, Inc. (ABVC) shares for innovation and growth in this field.
Sector
Healthcare
Industry
Biotechnology
CEO
Uttam Yashwant Patil
Employees
18
Headquarters
Fremont
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number